CDC claims Pfizer-BioNTech vaccine significantly reduces the risk of infection in children Pfizer-BioNTech vaccine
Two doses of Pfizer-BioNtech’s Kovid-19 vaccine in the age group of 5 years to 15 years, claim a new study. Omicron can significantly reduce the risk of infection in children with
Pfizer-BioNTech Vaccine Against Omicron Variant: The CDC of America has made a big statement related to the effectiveness of the Pfizer-BioNTech Vaccine for children to prevent coronavirus infection. In a new study published by the US Centers for Disease Control and Prevention, it has been claimed that two doses of Pfizer-BioNtech’s Kovid-19 vaccine are available in children aged 5 to 15 years. Omicron can reduce the risk of infection to a great extent.BioNtech Vaccine Against Omicron Variant In Hindi.)
Reduces the risk of infection with
– Omicronsymptoms of omicron infection and exposure to coronavirus infection. According to information provided by the CDC, about half of the children and adolescents who did not get the coronavirus vaccine did not show any symptoms despite being infected with Omicron.
The results of this CDC study show that children between the ages of 5 and 11 who took two doses of the Pfizer-BioNTech COVID-19 Vaccine (Pfizer-BioNTech Vaccine Against Omicron Variant) had Omicron variant infection a 31 percent and 12 percent reduction in the risk of infection in adolescent children aged 15 to 15 years was reduced by 59 percent.
Let us tell you that in the month of May 2021, Pfizer-BioNtech’s mRNA Kovid-19 vaccine was recommended by CDC’s advisory committee. Based on these recommendations, approval was given for children and adolescents aged 12 to 15 years, whereas, for children aged five to 11 years, on November 2, 2021.